These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 28435061)

  • 81. Review on Research about Traditional Chinese Medicine in Cancer Stem Cell.
    Wang Y; Feng L; Piao B; Zhang P
    Evid Based Complement Alternat Med; 2017; 2017():4505194. PubMed ID: 29234398
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Curcumin in VIP-targeted sterically stabilized phospholipid nanomicelles: a novel therapeutic approach for breast cancer and breast cancer stem cells.
    Gülçür E; Thaqi M; Khaja F; Kuzmis A; Önyüksel H
    Drug Deliv Transl Res; 2013 Dec; 3(6):. PubMed ID: 24363979
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Nanoparticles for Drug and Gene Delivery in Pediatric Brain Tumors' Cancer Stem Cells: Current Knowledge and Future Perspectives.
    Abballe L; Spinello Z; Antonacci C; Coppola L; Miele E; Catanzaro G; Miele E
    Pharmaceutics; 2023 Feb; 15(2):. PubMed ID: 36839827
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Combinatorial Strategies to Target Molecular and Signaling Pathways to Disarm Cancer Stem Cells.
    Catara G; Colanzi A; Spano D
    Front Oncol; 2021; 11():689131. PubMed ID: 34381714
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Tumor heterogeneity and its implication for drug delivery.
    Denison TA; Bae YH
    J Control Release; 2012 Dec; 164(2):187-91. PubMed ID: 22537887
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Targeting Cancer Stem Cells with Nanoparticle-Enabled Therapies.
    Burke AR; Singh RN; Carroll DL; Torti FM; Torti SV
    J Mol Biomark Diagn; 2012 Jul; Suppl 8():. PubMed ID: 24383043
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Chemotherapy targeting cancer stem cells.
    Liu H; Lv L; Yang K
    Am J Cancer Res; 2015; 5(3):880-93. PubMed ID: 26045975
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Cell-based drug-delivery systems: a possible solution to improve nanomedicine for cancer treatment?
    Chan WJ; Li H; Dehestani S
    Nanomedicine (Lond); 2022 Mar; 17(6):349-352. PubMed ID: 35023371
    [No Abstract]   [Full Text] [Related]  

  • 89. Macro-nanomedicine: Targeting the big picture.
    Lammers T
    J Control Release; 2019 Jan; 294():372-375. PubMed ID: 30521831
    [No Abstract]   [Full Text] [Related]  

  • 90. Clinically-relevant and predictive cancer models for nanomedicine evaluation.
    Satchi-Fainaro R; Florindo HF; Vicent MJ
    Adv Drug Deliv Rev; 2022 Apr; 183():114140. PubMed ID: 35134434
    [No Abstract]   [Full Text] [Related]  

  • 91. Proceedings of the Tenth International Nanomedicine and Drug Delivery Symposium, December 6–7, 2012, Atlantic City, NJ.
    J Control Release; 2013 Nov; 171(3):259-358. PubMed ID: 24795977
    [No Abstract]   [Full Text] [Related]  

  • 92. Clinical applications of nanomedicine in cancer therapy.
    Norouzi M; Amerian M; Amerian M; Atyabi F
    Drug Discov Today; 2020 Jan; 25(1):107-125. PubMed ID: 31586642
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Targeting metabolism to induce cell death in cancer cells and cancer stem cells.
    Pecqueur C; Oliver L; Oizel K; Lalier L; Vallette FM
    Int J Cell Biol; 2013; 2013():805975. PubMed ID: 23476653
    [TBL] [Abstract][Full Text] [Related]  

  • 94. [Resistant cancer cells cause the majority of cancer deaths. Time for a paradigm shift – nanomedicine offers new opportunities].
    Friberg S
    Lakartidningen; 2016 Sep; 113():. PubMed ID: 27622762
    [No Abstract]   [Full Text] [Related]  

  • 95. Cancer nanomedicine: Is targeting our target?
    Lammers T; Kiessling F; Ashford M; Hennink W; Crommelin D; Storm G
    Nat Rev Mater; 2016 Sep; 1(9):. PubMed ID: 27668091
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Cancer stem cells: at the forefront of personalized medicine and immunotherapy.
    Fiori ME; Villanova L; De Maria R
    Curr Opin Pharmacol; 2017 Aug; 35():1-11. PubMed ID: 28527911
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Exploring the dynamic interplay between cancer stem cells and the tumor microenvironment: implications for novel therapeutic strategies.
    Li YR; Fang Y; Lyu Z; Zhu Y; Yang L
    J Transl Med; 2023 Oct; 21(1):686. PubMed ID: 37784157
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Nimbolide-based nanomedicine inhibits breast cancer stem-like cells by epigenetic reprogramming of DNMTs-SFRP1-Wnt/β-catenin signaling axis.
    Mohapatra P; Madhulika S; Behera S; Singh P; Sa P; Prasad P; Swain RK; Sahoo SK
    Mol Ther Nucleic Acids; 2023 Dec; 34():102031. PubMed ID: 37771911
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Zinc-finger protein 750 mitigates malignant biological behavior of oral CSC-like cells enriched from parental CAL-27 cells.
    Xu C; Yang HL; Yang YK; Pan L; Chen HY
    Oncol Lett; 2022 Jan; 23(1):28. PubMed ID: 34868365
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Cancer stem cells and strategies for targeted drug delivery.
    Cao J; Bhatnagar S; Wang J; Qi X; Prabha S; Panyam J
    Drug Deliv Transl Res; 2021 Oct; 11(5):1779-1805. PubMed ID: 33095384
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.